Inactive Instrument

Neuralstem, Inc. Share Price NYSE

US64127R3021

End-of-day quote NYSE Other stock markets
- ^USD	-

06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell Small Cap Comp Growth Benchmark	CI
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 2500 Growth Benchmark	CI

Latest news : Neuralstem, Inc.

06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell Small Cap Comp Growth Benchmark	CI
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 2500 Growth Benchmark	CI
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 2000 Index	CI
06-29	Palisade Bio Receives FDA Clearance Of IND For PALI-2108 And Plans To Initiate Global Phase 2 ASCENTRA-UC Study In Ulcerative Colitis	CI
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 2000 Value Benchmark	CI
06-29	Palisade Bio Shares Rise After FDA Clears PALI-2108 for Phase 2 Trial	DJ
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell Microcap Value Benchmark Index	CI
06-29	Palisade Bio Gets FDA IND Clearance for Phase 2 PALI-2108 UC Study	MT
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell Microcap Growth Benchmark Index	CI
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 2000 Growth Benchmark	CI
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 3000E Growth Benchmark	CI
06-29	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell Microcap Index	CI
06-28	Palisade Bio, Inc.(NasdaqCM:PALI) added to Russell 3000E Value Benchmark	CI

More news

Analysts' recommendations: Neuralstem, Inc.

03-26	HC Wainwright Initiates Coverage on Palisade Bio With Buy Rating, $7 Price Target	MT
02-25	Stifel Initiates Palisade Bio at Buy With $5 Price Target	MT
01-09	B. Riley Initiates Palisade Bio at Buy With $7 Price Target	MT
17/11/23	Maxim Upgrades Palisade Bio to Buy From Hold, Price Target is $1.50	MT
16/05/23	Ladenburg Thalmann Adjusts Price Target on Palisade Bio to $16 From $25, Maintains Buy Rating	MT

More recommendations

Press Releases: Neuralstem, Inc.

07-10	Palisade Bio to Participate in the Leerink Partners Therapeutics Forum	AQ
06-29	Palisade Bio Receives FDA Clearance of IND for PALI-2108 and Plans to Initiate Global Phase 2 ASCENTRA-UC Study in Ulcerative Colitis	AQ
06-11	Palisade Bio Welcomes Biopharmaceutical Industry Veterans Robert Baltera and Jordan Zwick to its Board of Directors	AQ
06-10	Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn's Disease at New York Academy of Sciences Symposium	AQ
06-09	Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium	AQ

More press releases

News in other languages: Neuralstem, Inc.

29/01/24	MÄRKTE USA/Fester - Neue Rekordhochs dank sinkender Anleihezinsen
29/01/24	LATE BRIEFING - Unternehmen und Märkte
29/01/24	MÄRKTE USA/Kaum verändert - Vor Fed-Entscheid dominiert Zurückhaltung
29/01/24	MÄRKTE USA/Wall Street startet wenig verändert in Fed-Woche
29/01/24	MÄRKTE USA/Wall Street wenig verändert erwartet

More news

Seneca Biopharma, Inc., formerly Neuralstem, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for diseases of unmet medical need. It is focused on finding and acquiring new assets, sciences and technologies that provide therapies for patients. It intends to focus on developing a pipeline of biopharmaceuticals and commercializing those products.

Employees

Sector

More about the company

Market Cap	328M 288M 267M 245M 464M 31.4B 473M 3.18B 1.25B 15.42B 1.23B 1.2B 53.25B	P/E 2026 *	-7.92x	P/E 2027 *	-6.62x
Enterprise Value	234M 205M 190M 175M 331M 22.38B 337M 2.26B 888M 10.99B 878M 859M 37.96B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	-	Yield 2026 *	-	Yield 2027 *	-

	2026 *	2027 *
Net sales	-	-
Net income	-50.98M -44.72M -41.42M -38.11M -72.08M -4.88B -73.48M -494M -194M -2.4B -191M -187M -8.28B	-66.28M -58.13M -53.84M -49.54M -93.7M -6.34B -95.52M -642M -252M -3.12B -249M -243M -10.76B
Net Debt	-94.2M -82.62M -76.52M -70.41M -133M -9.02B -136M -912M -358M -4.43B -354M -346M -15.29B	-331M -290M -269M -248M -468M -31.7B -477M -3.21B -1.26B -15.57B -1.24B -1.22B -53.76B

Neuralstem, Inc. Share Price NYSE

Stocks

US64127R3021

Valuation: Neuralstem, Inc.

Latest news : Neuralstem, Inc.

Analysts' recommendations: Neuralstem, Inc.

Press Releases: Neuralstem, Inc.

News in other languages: Neuralstem, Inc.

Financials

Company Profile